Synapse

← Cancer Research Communications

Papers in Cancer Research Communications

Page 1 · newest first

  1. Resistance to first-generation TRK inhibitor therapy in NTRK fusion-positive adult and pediatric cancers conditions next-generation TRK inhibitor activity: a phase I study of selitrectinibCancer Research Communications · 2026
  2. Cardiopulmonary Fitness and Neurocognitive Function in Long-term Childhood Hodgkin Lymphoma SurvivorsCancer Research Communications · 2026
  3. Tissue factor-specific sdAb radiotracers for molecular imaging in solid tumorsCancer Research Communications · 2026
  4. Social vulnerability index associates with chronic lymphocytic leukemia survival rates in the Detroit tri-county areaCancer Research Communications · 2026
  5. Primary mediastinal large B-cell lymphoma genomic profiling demonstrates thymic B-cell identity and frequent aberrant somatic hypermutationCancer Research Communications · 2026
  6. Distinguishing Features of Radiation-Induced from Sporadic Thyroid Cancers after the Chornobyl Nuclear Power Plant AccidentCancer Research Communications · 2026
  7. Irradiation induces an epigenetically plastic CD44low persister cell population associated with tumor regrowth in colorectal cancerCancer Research Communications · 2026
  8. Combination Therapy with AKT and MEK Inhibitors is Effective in Patient-Derived Models of Adrenocortical CarcinomaCancer Research Communications · 2026
  9. A Phase 1 Trial of Low-dose Gemcitabine Combined with ATR Inhibitor Elimusertib for Advanced Solid TumorsCancer Research Communications · 2026
  10. A Practical Guide to Choosing Multiple-Comparison Tests for Efficacy Analysis in Small-Sample Patient-Derived Xenograft StudiesCancer Research Communications · 2026
  11. MCL1 may not mediate chemoresistance in cancer cellsCancer Research Communications · 2026
  12. Anti–PD-L1 glycoengineering enhances tumor killing through coordinated interactions between PD-L1⁺ DCs and CD16A⁺ cytotoxic lymphocytesCancer Research Communications · 2026
  13. A First-in-Human, Phase I Trial of MK-6598, an Inhibitor of the Immune Checkpoint IL4I1, With or Without Pembrolizumab for Advanced Solid TumorsCancer Research Communications · 2026
  14. Mechanisms of pregnancy-associated triple negative breast cancer risk: insights from spatial omicsCancer Research Communications · 2026
  15. Prognostic Modeling Integrating RAS and SMAD4 Status in Patients with BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal CancerCancer Research Communications · 2026
  16. Cancer cell CD73 loss promotes a dual inflammatory and immunosuppressive microenvironment in endometrial carcinomaCancer Research Communications · 2026
  17. TRPM4 promotes ErSO-mediated oncosis-like cell death in prostate cancer cellsCancer Research Communications · 2026
  18. Comparative analysis of ovarian cancer tumor-infiltrating T cells with those in melanoma and before and after PD-1 blockadeCancer Research Communications · 2026
  19. Biomarker Modulation by Aspirin and Metformin for Colorectal Cancer Prevention: Results from the ASAMET Randomized Phase II TrialCancer Research Communications · 2026
  20. Paxalisib with Trastuzumab for HER2-Positive Metastatic Breast Cancer with Active Brain Metastases: A Phase II Trial with Integrated Plasma and CSF ctDNA AnalysesCancer Research Communications · 2026
  21. microRNA expression in macrophages regulates antibody-dependent effector function and B cell lymphoma therapyCancer Research Communications · 2026
  22. The use of TF-Ag-α to selectively capture tumor-derived extracellular vesicles and enhance the predictive performance of extracellular vesicle PD-L1 for response to immune checkpoint inhibitorsCancer Research Communications · 2026
  23. Androgen-mediated T cell suppression drives sex bias in head and neck squamous cell carcinomaCancer Research Communications · 2026
  24. Nicotinic acid restriction potentiates NAMPT inhibition in acute myeloid leukemia xenograft models.Cancer Research Communications · 2026
  25. Elucidating the Gene Expression Signature of Rosai-Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes InitiativeCancer Research Communications · 2026
  26. ERX 208 induces endoplasmic reticulum stress and suppresses DNA damage repair to enhance chemotherapy sensitivityCancer Research Communications · 2026
  27. Phase 1a Evaluation of LP-184 in Recurrent Glioblastoma: Safety, Pharmacokinetics, and Translational Optimization of CNS ExposureCancer Research Communications · 2026
  28. HIV and Antiretroviral Therapy Influence Tumor Microenvironment Architecture, Subclonal Evolution, and Immune Evasion Strategies in Diffuse Large B-Cell LymphomaCancer Research Communications · 2026
  29. Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: a Multicenter Prospective Observational Study (COSMOS-MEL01)Cancer Research Communications · 2026
  30. Lymph node lymphatic PD-L1 regulates tumor-infiltrating T cells in immune checkpoint-sensitive melanomaCancer Research Communications · 2026
  31. Setanaxib Added to Pembrolizumab for Fibroblast-Rich, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: a Phase 2 Randomized StudyCancer Research Communications · 2026
  32. Dual CHK1 and WNT inhibition as a synergistic therapy for gastrointestinal neuroendocrine carcinomaCancer Research Communications · 2026
  33. Auranofin potentiates cisplatin response in the setting of context-dependent NOTCH-associated signaling states in endometrial cancerCancer Research Communications · 2026
  34. Clinical and Molecular Profiles of Treatment-Emergent Small Cell Neuroendocrine Prostate Cancers in the Era of Intensified Systemic TherapiesCancer Research Communications · 2026
  35. Dissociated response to immune checkpoint inhibition in head and neck squamous cell carcinoma is common and exhibits distinct clinical outcomesCancer Research Communications · 2026
  36. Breast cancer protective genetic variant common in women of Indigenous American genetic ancestry is a cis-eQTL for RMND1, ARMT1, and CCDC170 in HER2-enriched tumor subtypesCancer Research Communications · 2026
  37. Gustave Roussy Immune (GRIm) score validation in patients treated with Bispecific CD3 T-cell engagers in phase I clinical trials.Cancer Research Communications · 2026
  38. SHIVA02 trial: Using patients as their own controls to assess efficacy of therapies based on molecular profiling in patients with refractory cancerCancer Research Communications · 2026
  39. A Phase 1 Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients With Advanced Gastrointestinal CancersCancer Research Communications · 2026
  40. Improving long-read somatic structural variant calling with pangenome and de novo personal genome assemblyCancer Research Communications · 2026
  41. Transcriptome-based synthetic lethality predictions to improve targeted therapy/immunotherapy treatment prioritization in non-metastatic breast cancer: BC-SELECTCancer Research Communications · 2026
  42. Window-of-Opportunity Study Utilizing Preoperative Cetuximab in Patients with Head and Neck CancerCancer Research Communications · 2026
  43. The role of germline transposable element insertions in pediatric cancer predispositionCancer Research Communications · 2026
  44. Supermeres containing Discoidin Domain Receptor 1 extracellular domain promote collagen alignment and immune exclusion in microsatellite stable colorectal cancerCancer Research Communications · 2026
  45. Vitronectin enrichment in prostate cancer liver metastases promotes adhesion and survivalCancer Research Communications · 2026
  46. Ribonucleotide Reductase Inhibition Triggers Ferroptosis in Genetically Defined Subsets of Non-Small Cell Lung CancerCancer Research Communications · 2026
  47. The GENIE Data Model: A Solid Tumor, Person-Centric Framework for Scalable, Harmonized Precision Oncology Data CollectionCancer Research Communications · 2026
  48. Spindle Assembly Checkpoint Competency Determines Sensitivity to KIF18A Inhibition in Small-Cell Lung CancerCancer Research Communications · 2026
  49. A Phase 1b/2 Study of Atezolizumab in Combination with Thiopurine Therapy in Patients with Metastatic Solid Tumors and Intermediate Tumor Mutational BurdenCancer Research Communications · 2026
  50. Community-Based Hereditary Breast and Ovarian Cancer Family History Assessment and Genetic Testing among Spanish-Speaking Hispanic/Latina Women in CaliforniaCancer Research Communications · 2026